Respirovirus infectious disease

Summary

Respirovirus infectious disease (MONDO:0005940) is a disease. A subtype of Paramyxoviridae infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	respirovirus infectious disease
Mondo ID	MONDO:0005940
EFO	EFO:0007465
MeSH	D010253
UMLS	C3714630
MedGen	811417
Is cancer (heuristic)	no

Also known as: infections, Respirovirus

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Mononegavirales infectious disease › Paramyxoviridae infectious disease › respirovirus infectious disease

Related subtypes (5): mumps infectious disease, Avulavirus infectious disease, henipavirus infectious disease, morbillivirus infectious disease, parainfluenza infectious disease

Subtypes (2): parainfluenza virus type 3 infectious disease, parainfluenza virus type 1 infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.